b'INDUSTRY NEWS(contd)TrypTherapeuticsPartnerswithAltasciencestoConduct Exploratory Studies for Proprietary Psilocybin-Based Formulation CalvertLaboratories,anAltasciencescompany,hasbeenselectedtodesignandconductexploratorystudiesrelatedtoTryps Psilocybin-for-Neuropsychiatric Disorders (PRNTM) program. These studieswillbeaimedtowardsgeneratingtoxicologyandblood exposure level data. Read the press release.New Hire: Bruce Frank Joins Altasciences as Vice President, CDMO Operations Brucehas30yearsofexperiencewithproductformulationand development,leadingdiscoverychemistry,newtechnology evaluation,andprojectmanagementinitiatives,inbothsmalland large biotechnology firms, making him a highly regarded leader in the CDMO space. Read the press release.Altasciences Launches New Podcast Series: The Many Faces of Recreational Drug UseAmixtureofinterviewsandcommentary,thisnewpodcastseries exploresthepersonaldrughistoryofrealpeople.Eachepisode featuresacandidconversationwithaparticipantwhoeitheruses drugs recreationally or who is suffering with substance use disorder. Throughouttheepisodes,AltasciencesDr.BeatriceSetnik,Chief Scientific Officer, and Dr. Debra Kelsh, MD, Senior Principal Investigator and Psychologist, will offer commentary on key moments from the interview. Watch the first episode.'